 Informed consent will be obtained and following confirmation of eligibility and disease assessment, study participants will be randomised allocated by chance to take either CyColTM, or placebo, orally once every day for four weeks. Study visit assessments will include blood and stool tests, physical examinations and flexible sigmoidoscopies inspection of the bowel wall using a flexible camera. 